Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 (n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Skendros, Panagiotis, Germanidis, Georgios, Mastellos, Dimitrios C., Antoniadou, Christina, Gavriilidis, Efstratios, Kalopitas, Georgios, Samakidou, Anna, Liontos, Angelos, Chrysanthopoulou, Akrivi, Ntinopoulou, Maria, Kogias, Dionysios, Karanika, Ioanna, Smyrlis, Andreas, Cepaityte, Dainora, Fotiadou, Iliana, Zioga, Nikoleta, Mitroulis, Ioannis, Gatselis, Nikolaos K., Papagoras, Charalampos, Metallidis, Simeon, Milionis, Haralampos, Dalekos, George N., Willems, Loek, Persson, Barbro, Manivel, Vivek Anand, Nilsson, Bo, Connolly, E. Sander, Iacobelli, Simona, Papadopoulos, Vasileios, Calado, Rodrigo T., Huber-Lang, Markus, Risitano, Antonio M., Yancopoulou, Despina, Ritis, Konstantinos, Lambris, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385148/
https://www.ncbi.nlm.nih.gov/pubmed/35977025
http://dx.doi.org/10.1126/sciadv.abo2341

Ejemplares similares

Ejemplares similares